Side-by-side · Research reference
MT-1vsOvagen
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AFDA-ApprovedHUMAN-REVIEWED9/51 cited
BTheoreticalHUMAN-REVIEWED2/42 cited
MT-1
α-MSH Analogue · FDA-Approved
SQ Implant · 60-Day Release
Ovagen
Khavinson Bioregulator · Ovarian
OvarianTarget tissue
Di/Tri-peptidePeptide length
AnimalEvidence tier
Oral / SQ · Protocol varies
01Mechanism of Action
Parameter
MT-1
Ovagen
Primary target
Melanocortin-1 receptor (MC1R) on melanocytesLangan 2010
Ovarian tissue chromatin complexes
Pathway
α-MSH analogue → MC1R activation → cAMP elevation → MITF transcription → eumelanin synthesis
Tissue-specific peptide → Nuclear chromatin binding → Gene expression modulation → Cellular differentiation
Downstream effect
Increased melanogenesis, photoprotection, reduced UV sensitivityLangan 2010
Proposed ovarian functional support, fertility regulation, hormonal homeostasis restoration
Feedback intact?
Yes — exogenous MC1R agonism does not suppress endogenous α-MSH production
Presumed physiological — Khavinson peptides described as regulatory, not replacement
Origin
Synthetic 13-AA peptidomimetic with norleucine (position 4) and D-phenylalanine (position 7) substitutions for metabolic stabilityChawathe 2026
Extracted from bovine/porcine ovarian tissue; short synthetic peptides (2–4 amino acids)
Antibody development
—
—
02Dosage Protocols
Parameter
MT-1
Ovagen
Standard dose
16 mg subcutaneous implant
FDA-approved formulation (Scenesse).
10–20 mg / day (oral) or 1–2 mg SQ
Extrapolated from Khavinson-school protocols; no ovagen-specific PubMed dose studies.
Frequency
Every 60 days
Sustained release implant — no daily administration required.
Once daily or cyclical (10–20 days per month)
Cyclical protocols common in Khavinson bioregulator tradition.
Evidence basis
Phase 3 RCT / FDA-approved orphan drug
Theoretical / Russian-tradition
Indication
Erythropoietic protoporphyria (EPP)
Narrow FDA approval — not licensed for cosmetic tanning.
—
Duration
Seasonal use (spring–autumn typical)
Aligned with peak UV exposure months.
4–12 weeks per cycle
Khavinson protocols typically 1–3 months; repeat cycles as needed.
Route
Subcutaneous implant — upper arm or abdomen
Oral (capsule) or subcutaneous
Oral absorption assumed for short peptides; SQ route mirrors other Khavinson bioregulators.
Stability
Norleucine/D-Phe substitutions enhance peptidase resistance
Modified structure vs endogenous α-MSH (Met⁴, L-Phe⁷).
—
04Side Effects & Safety
Parameter
MT-1
Ovagen
Nausea
Common (>10%) — mild, transient
—
Implant site reaction
Erythema, bruising, tenderness at insertion site
—
Hyperpigmentation
Generalised tanning (therapeutic effect), darkening of freckles/neviLangan 2010Habbema 2017
Expected melanogenic response — complicates pigmented lesion surveillance.
—
Melanocytic changes
Rapid pigmentation of existing nevi; new melanocytic lesions reported with unregulated useHabbema 2017
Requires dermatologic monitoring; theoretical melanoma concern with chronic stimulation.
—
Headache
Occasional (MC1R-independent melanocortin effects)
—
Photosensitivity (paradoxical)
Rare phototoxic reactions despite melanin increase
—
Contamination risk (unregulated)
Impurity, infection, blood-borne virus transmission from illicit melanotan productsLangan 2010Habbema 2017
Applies to internet/gym-sourced 'melanotan' — not FDA-approved Scenesse.
—
Reported adverse events
—
None documented in indexed literature
Theoretical hormonal effects
—
Ovarian stimulation — monitor for estrogen-sensitive conditions
Injection site reaction
—
Possible mild erythema (SQ route)
Long-term safety
—
Unknown — no PubMed-indexed RCTs
Absolute Contraindications
MT-1
- ·Hypersensitivity to afamelanotide or excipients
- ·Hepatic impairment (no safety data)
- ·Renal impairment (no safety data)
Ovagen
- ·Active hormone-sensitive malignancy (breast, ovarian, endometrial)
- ·Pregnancy
Relative Contraindications
MT-1
- ·History of melanoma or atypical nevi (melanocortin receptor stimulation concern)Habbema 2017
- ·Pregnancy/lactation (insufficient data)
- ·Photosensitive dermatoses (other than EPP)
Ovagen
- ·History of estrogen-sensitive tumors (monitor)
- ·Polycystic ovary syndrome (PCOS) — theoretical ovarian hyperstimulation risk
- ·Endometriosis or fibroids (estrogen-responsive conditions)
05Administration Protocol
Parameter
MT-1
Ovagen
1. Implant insertion
Performed by trained healthcare provider. Sterile technique. Small incision in upper arm (triceps) or lower abdomen using trocar. 16 mg rod (4 mm × 1.5 cm) inserted subcutaneously.
Typical dose: 10–20 mg once daily. Capsule form — taken on empty stomach, 20–30 min before meals. Khavinson tradition suggests morning administration.
2. Site care
Pressure applied post-insertion. Sterile dressing × 24 hrs. Avoid strenuous activity for 24–48 hrs to prevent extrusion.
1–2 mg per injection. Reconstitute lyophilised powder with sterile water if required. Inject into abdomen or thigh; rotate sites.
3. Release kinetics
Slow biodegradable polymer matrix releases afamelanotide over 60 days, maintaining therapeutic plasma levels without daily dosing.
Common pattern: 10–20 days on, 10 days off. Aligns with menstrual cycle phases in some protocols. Repeat cycles for 2–3 months, then assess.
4. Repeat dosing
New implant every 60 days during high UV season (spring–autumn in temperate climates). Rotate implant sites to avoid scarring.
Lyophilised: room temperature, light-protected. Reconstituted: refrigerate 2–8 °C, use within 7–14 days.
5. Monitoring
Baseline and periodic dermatologic exams to document pigmented lesions. Patient education on self-examination for new/changing nevi.
—